Worldwide alliance of amyloidosis patient organizations and support groups looking to make contributions to the quality of care of amyloidosis patients
WE UNDERSTAND THE UNMET NEEDS OF THOSE LIVING WITH ATTR
Transthyretin amyloidosis (ATTR) is a complex, rapidly progressive, and ultimately fatal disease that effects many organs of the body, most notably the heart and nervous system. Non-specific symptoms and limited disease awareness often delay diagnosis of ATTR; on average, diagnosis occurs more than 3 years after initial symptom onset. This delay can have devastating consequences. The median survival from time of diagnosis is less than 4 years for ATTR patients with cardiac involvement.
Progression of ATTR causes significant morbidity, impacts productivity and quality of life, and creates a significant economic burden from the costs associated with progressively greater patient needs for supportive care. ATTR also disproportionately impacts certain patient populations—for example, 3% to 4% of all Black Americans carry a V122I TTR mutation that substantially increases their likelihood of developing cardiomyopathy.
There are limited treatment options currently that address the underlying causes of ATTR, and commonly prescribed therapies for heart failure and cardiomyopathy have limited efficacy in treating ATTR. There is great urgency to meet the needs of individuals with ATTR, particularly when it comes to earlier diagnosis and additional treatment options in order to improve quality of life and increase time to spend with loved ones.
OUR PURPOSE
Eidos is actively developing an investigational oral medicine for ATTR named acoramidis (AG10). Acoramidis is a small molecule, designed to selectively stabilize TTR and prevent the formation of amyloid fibrils that cause ATTR. We are working quickly to advance its development—knowing that every minute counts for patients and families suffering from this devastating disease.
OUR PROMISE
At Eidos, we strive to establish and build enduring and supportive relationships within the ATTR community. We are committed to approaching these relationships with honesty, integrity, and transparency.
We respect the independence of patient organizations and the unique perspective of every advocate, patient, and family member.
We actively seek to include the perspective of patients, families, and advocates in the drug development process by listening and learning from them.
Patient Stories
PATIENT Resources
Amyloidosis Specific
Rare Disease
Clinical Trial
Access Policy
At Eidos Therapeutics, we are committed to approaching our relationships with our patients and their families with honesty, integrity, and transparency. We recognize that some patients may not be eligible to participate in our clinical trials. While Eidos does not have a formal expanded access program in place, we consider requests for expanded access only on a case-by-case basis. Inquiries regarding expanded access may be sent to ExpandedAccess@eidostx.com.